Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vancomycin Prophylaxis for Recurrent C. difficile
NCT02237859Phase 4
Key facts
- Status
- Unknown
- Start
- Aug 2014
- Primary completion
- Aug 2016
- Countries
- 1
- Sponsor
- Corewell Health
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Drugs
- vancomycin
- Conditions
- Clostridium difficile infection (CDI)
01
Overview
Phase 4, randomised, double-blind trial in Clostridium difficile infection (CDI) comparing Vancomycin with Placebo (2 arms). Primary endpoint: Incidence of recurrent Clostridium difficile infection at 2 years. Status: unknown.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Vancomycin
Vancomycin 125 mg PO QD for 10 days
Placebo
Placebo PO QD for 10 days
03
Endpoints
Primary
Incidence of recurrent Clostridium difficile infection
Beyond the preview
Go deeper on NCT02237859.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02237859.